Final Results

RNS Number : 6615N
Dechra Pharmaceuticals PLC
06 September 2011
 



 

Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Tuesday, 6 September 2011

Dechra® Pharmaceuticals PLC

("Dechra")

An International Veterinary Pharmaceutical Business

Preliminary Results for the year ended 30 June 2011

 


Year ended

30 June 2011

Year ended

30 June 2010


·      Revenue

£389.2m

£369.4m

+5.4%

·      Underlying operating profit*

£31.8m

£28.2m

+12.9%

·      Operating profit

£21.7m

£19.9m

+9.3%

·      Underlying profit before taxation*

£30.1m

£26.1m

+15.4%

·      Profit before tax

£18.5m

£17.7m

+4.4%

·      Underlying earnings per share*




Basic

34.33p

29.50p

+16.4%

Diluted

34.22p

29.39p

+16.4%

·      Earnings per share




Basic

21.33p

19.97p

+6.8%

Diluted

21.26p

19.89p

+6.9%

·      Dividend




Final

8.40p

7.20p

+16.7%

Total

12.10p

10.50p

+ 15.2%

·      Net borrowings

£34.1m

£6.7m


 

·      Fifth successive year of double digit underlying earnings per share growth

·      Strong growth from branded veterinary products

·      Investment in product pipeline increased

·      High cash inflow in second half

·      Two earnings enhancing acquisitions completed and integrated

·      Strong balance sheet with net borrowings 0.98 times underlying EBITDA

* Non-underlying items comprise amortisation of acquired intangibles, acquisition expenses, rationalisation costs, payments to acquire technology for the research and development programme, impairment charges, loss on extinguishment of debt and the unwinding of discounts on deferred and contingent consideration

 

Enquiries:


Ian Page, Chief Executive

Fiona Tooley, Director

Simon Evans, Group Finance Director

Keith Gabriel, Senior Account Manager

Dechra Pharmaceuticals PLC

Citigate Dewe Rogerson

Today:

+44 (0) 20 7638 9571 (until 12.30pm)

Today:

+44 (0) 207 638 9571

Mobile:

+44 (0) 7775 642222 (IP) or

Mobile:

+44 (0) 7785 703523 (FMT) or


+44 (0) 7775 642220 (SE)


+44 (0) 7770 788624 (KG)

Thereafter:

+44 (0) 1782 771100

Thereafter:

+44 (0) 121 362 4035

www.dechra.com

corporate.enquiries@dechra.com

Sector: Premium Listing (Pharmaceuticals): DPH

 

Forward-Looking Statements

This document contains certain forward-looking statements.  The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involving a degree of uncertainty.  Therefore, nothing in this document should be construed as a profit forecast by the Company.



Dechra Pharmaceuticals PLC

Preliminary Results for the year ended 30 June 2011

 

STATEMENT BY THE CHAIRMAN, MICHAEL REDMOND

 

Consistent Double Digit Earnings Growth

The Group has achieved its fifth successive year of double digit underlying earnings growth and made significant strategic progress during the year.  Two acquisitions, which will be earnings enhancing in the first full year of ownership, have been completed and integrated into the business, our branded products have continued to outperform the market, several new products have been launched and our international scope has increased.  Furthermore, we have continued to make advancements with our product development pipeline and have increased investment in people and infrastructure to ensure growth is sustained in the future.

 

Financial Highlights

Revenue increased by 5.4% from £369.4 million to £389.2 million; underlying operating profit increased by 12.9% from £28.2 million to £31.8 million.  The increase in underlying operating margin from 7.6% to 8.2% is a reflection of the growth of our high margin pharmaceutical business, particularly in the USA.

 

The underlying net finance expense was £1.8 million compared to £2.1 million in 2010.  Additional net foreign exchange gains of £0.8 million were partially offset by interest on additional bank borrowings to finance the DermaPet®and Genitrix® acquisitions.

 

Underlying profit before taxation increased by 15.4% from £26.1 million to £30.1 million whilst underlying earnings per share rose by 16.4% from 29.50 pence to 34.33 pence.

 

Reported operating profit was £21.7 million (2010: £19.9 million) whilst profit before taxation was £18.5 million (2010: £17.7 million).  Reported earnings per share was 21.33 pence (2010: 19.97 pence).

 

After a cash outflow in the first half of the financial year, there was a strong cash inflow in the second half with net borrowings reducing from £49.6 million at 31 December 2010 to £34.1 million at 30 June 2011.  The increase from £6.7 million at 30 June 2010 is due to the acquisitions made during the year.

 

Dividend

In line with our progressive dividend policy and our confidence in the business, the Directors are recommending an increase in the final dividend to 8.40 pence per share (2010: 7.20 pence per share).  This, together with the interim dividend of 3.70 pence per share (2010: 3.30 pence per share), makes a total dividend for the year of 12.10 pence per share (2010: 10.50 pence per share), a 15.2% increase.

 

The total dividend is covered 2.6 times by profit after taxation after adding back amortisation of acquired intangibles (2010: 2.6 times).

 

The final dividend, which is subject to Shareholder approval at the Annual General Meeting to be held on Friday 4 November 2011, will be paid on 25 November 2011 to Shareholders on the Register at 11 November 2011.  The date shares become ex-dividend is 9 November 2011.



People

There have been no senior management changes during the year; however, there have been a number of changes in respect of our Non-Executive Board members.  Following ten years of service, Malcolm Diamond MBE retired as Senior Independent Non-Executive Director and Chairman of the Remuneration Committee in November 2010.  We would like to thank Malcolm for his valued support and contribution to the business over this period.  Dr Chris Richards was appointed as an Independent Non-Executive Director from 1 December 2010.  Chris is currently Chairman of Arysta LifeScience Corporation, the world's largest privately owned crop protection company.  He brings with him over 20 years of international management experience.  Neil Warner has undertaken the role of Senior Independent Non-Executive Director and Bryan Morton has assumed the role of Chairman of the Remuneration Committee.

 

On behalf of the Board and our Shareholders I would like to thank all our employees for their hard work and dedication throughout the year.

 

Corporate Governance

During the year the Board has focused on consolidating the medium to long term strategy of the business to ensure that the Group continues to deliver and maintain value for our stakeholders.  As Chairman, one of my prime roles is to ensure that the Board has the right mix of skills and experience to assist the Executive Directors in the progression and implementation of this Group strategy.

 

During the year a detailed internal board evaluation programme was undertaken. The process was well received by the Directors and a number of constructive suggestions were highlighted which should assist in strengthening the Board over the coming year.  The evaluation highlighted the enthusiasm and ambition of the Board to continue to grow the business.

 

Prospects

Although footfall through veterinary practices has declined and the general economic climate remains uncertain we are continuing to demonstrate solid growth in markets in which we trade.  Our branded product range, the focus of our key strategic objective, continues to grow strongly.

 

To sustain this growth we have increased investment in product development, extended the geographies in which we operate, acquired complementary businesses and increased the number of people within sales and marketing.  We believe, therefore, that we are well positioned to ensure future solid growth is maintained and Shareholder value enhanced.



Dechra Pharmaceuticals PLC

Preliminary Results for the year ended 30 June 2011

 

REVIEW BY THE CHIEF EXECUTIVE, IAN PAGE

 

Introduction

The Group has continued to make good financial and strategic progress during the year.  The markets in most of the countries in which we trade have demonstrated growth, although there has been a decline in footfall through veterinary practices, especially in the companion animal sector.  This decline has been offset in the UK by reasonably strong growth in the livestock sector and by a significant increase in veterinary products being purchased online as price conscious consumers look to reduce the costs of animal welfare; Dechra, in our UK distribution business, is currently underweight in both these low margin sectors.  Within these market dynamics and against the background of continued global economic uncertainty, Dechra has performed strongly and, for the fifth consecutive year, produced double digit underlying earnings per share growth.  This success is a reflection of the strength of the Group and the ongoing delivery of the underlying strategy.  Furthermore, we have continued to invest in our infrastructure and product development pipeline and have made two earnings enhancing acquisitions to ensure we are well positioned to maintain good future growth prospects.

 

Our Strategy for Delivering and Maintaining Value

The Group has a clear strategy for growth by providing novel and specialist products together with innovative services to the veterinary profession.  Additionally, we provide contract manufacturing services to other pharmaceutical companies.

 

Products

The primary strategic objective of the Group is to develop a high growth, cash generative veterinary products business.  This is achieved by increased market shares of existing products and increasing the depth of the product range by:

 

·      pharmaceutical development of novel companion animal and equine products;

·      approval of pharmaceutical generic products;

·      the continued development and innovation of our branded pet diets; and

·      acquiring or in-licensing specialist pet products which can be marketed through existing sales and customer channels.

 

Furthermore, we are:

 

·      increasing geographical coverage through the creation of our own subsidiaries in countries where we are not currently represented; and

·      improving and developing sales growth through our export partners in non-subsidiary territories.

 

Services

The key strategic objectives in this segment are to:

 

·      continue improving logistics excellence;

·      maintain or reduce operating costs as a percentage of sales;

·      improve our service offerings relative to our competitors; and

·      position the businesses so that our customers and ourselves are best placed to take advantage of a changing marketplace.



Manufacturing

The key strategic objective of manufacturing is to effectively and economically produce our own veterinary pharmaceutical product range.  However, we have been successful in developing a contract manufacturing business by strategic implementation of:

 

·      therapeutic sector specialisation;

·      provision of a full service, from formulation and development through to manufacturing and packaging; and

·      the ability to offer our customers a wide range of scale, dosage forms and packaging formats.

 

Acquisitions

Two acquisitions were completed in the period.

 

DermaPet

DermaPet, a Florida based dermatological business, was acquired in October 2010 for a potential total consideration of US$64.0 million.  The acquisition strengthened our position as a leader in the worldwide veterinary dermatological market.  As a result, we have been able to significantly increase our US sales and marketing capabilities.  DermaPet has now been fully integrated into DVP US and expected sales and cost synergies are beginning to be realised.  We have modernised the packaging and are presenting it in Dechra livery.  The Group has also identified opportunities to increase sales and geographical coverage of this range within Europe.

 

Genitrix

In December 2010 we completed the acquisition of Genitrix, a privately owned veterinary company with a range of products complementary to Dechra's, for a potential total consideration of £6.4 million. The Genitrix brands are currently sold exclusively within the United Kingdom.  The rationalisation of the business was completed at the end of January 2011 with the closure of their warehouse and office facility.  A number of the Genitrix sales team have been appointed within the Dechra Group and cost synergies are now being realised. 

 

The main future strategic objective is to extend the Genitrix product range into other EU territories.  Libromide®, a recently approved canine epilepsy product for the UK, is being taken through Mutual Recognition to gain approval throughout Europe.  Two other products, Xeno® and RIP Fleas®, are also being considered for launch in other selected territories.

 

The Business and its Markets

Dechra operates under four segments:

 

·      Product Development;

·      European Pharmaceuticalswhich comprises Dechra Veterinary Products Europe ("DVP EU") and Dales® Pharmaceuticals ("Dales");

·      US Pharmaceuticals comprising Dechra Veterinary Products US ("DVP US"); and

·      Services comprising National Veterinary Services ("NVS®") and our Laboratories, NationWide Laboratories ("NWL") and Cambridge Specialist Laboratory Services ("CSLS").

 

The Group employs 1,010 people, operates out of 14 countries and exports products globally.

 

Product Development

The ongoing development of our specialist branded veterinary exclusive products is a key part of the Group's future growth plans.



Development Strategy

The Group has a strategic programme to increase its product portfolio.  The main criteria for assessing a product's potential for inclusion in the development pipeline are:

 

·      risk adjusted return on investment;

·      market potential and future growth opportunities;

·      geographical scope;

·      target species; and

·      the ability to sell and market through existing distributor and veterinary customer channels.

 

Our product development is concentrated in three areas:

 

·      Prescription only veterinary medicines ("POMs") for dogs, cats and horses.  We target products in specialist therapeutic areas and focus on novel ideas in underserved markets.  Most of our projects utilise existing pharmaceutical entities that are typically used within the human market and therefore the majority of product creation is development and not research based.

·      Therapeutic pet diets for dogs and cats.  Products are formulated and trialled to provide optimum nutrition for animals diagnosed with various medical conditions.

·      Unlicensed medicines, shampoos and supplements for dogs, cats and horses.  These products, on the whole, are intended for veterinary recommendation and in most cases will complement the therapeutic areas in which our POMs are targeted.

 

Development Achievements

The Group has continued to increase investment in product development with an 11.9% increase in expenditure over the corresponding period last year.  The development team has been increased to 25 people who are located in the United States, United Kingdom and Denmark.  Dosage form development work is conducted in the UK; regulatory work is conducted in the UK and Denmark and the majority of safety and efficacy trials are controlled by our US team.  There have been several approvals within the year:

 

·      Equidone® Gel, a specialist novel equine product, in the US;

·      Vetoryl®, the Group's largest product, in Japan;

·      10mg Vetoryl, which increases dosing options, in Australia;

·      Felimazole® 2.5mg, low dose preparation, approved in the Nordics;

·      Malaseb®, our dermatological product, recently licensed in mainland Europe is now approved in Norway;

·      Clavudale®, an antibiotic generic, throughout Europe via the Mutual Recognition procedure;

·      Urilin®, a bitch incontinence product, throughout Europe via the Mutual Recognition procedure;

·      Rycarfa®, a flavoured analgesic tablet, in the EU;

·      Alvegesic®, an analgesic injection, in the UK; and

·      Fiprodog®, a generic flea product in the UK.

 

Alvegesic, Rycarfa and Fiprodog are products which were gained through licensing agreements with European partners.

 

We have also achieved a number of other regulatory successes including:

 

·      the transfer of the Marketing Authorisations of the Genitrix products and Vetoryl from our previous EU marketing partners to Dechra;

·      the regulatory changes needed to transfer the manufacturing of Canaural® and Fuciderm® in-house;

·      work has begun on the difficult regulatory task of transferring the ophthalmic products, acquired from Nycomed for the US market last year, into a new manufacturer.



Three new diet ranges have been developed:

 

·      Canine Omega Support Diet: an effective support for a number of clinical conditions including the treatment of allergic dermatitis and for recovery from cancer and canine heart failure;

·      Feline Crystal Diet: a newly formulated cat diet optimised for the long term prevention of struvite crystals and prevention of recurrence of struvite crystals and uroliths; and

·      a certified organic range which are the first organic diets targeted for sale through veterinary practices.  These are palatable and nutritionally balanced diets for healthy pets.

 

Product Pipeline

As can be demonstrated by the achievements outlined earlier in this report, our product pipeline continues to deliver novel pharmaceuticals, generic pharmaceuticals, line extensions, approvals of existing products into new territories and new innovative pet diets.

 

New Chemical Entities

Development of new molecules to the veterinary profession is ongoing.  Significant progress has been made on an equine lameness product, with both the safety and efficacy studies being completed.  Unfortunately, there has been a six month delay as we have had to change the outsourced manufacturer.  All other novel products, outlined in the following table, continue to make progress.  We have, over the period, conducted two 'proof of concept' studies, one of which, a canine dermatological product, has been added to the development programme.  We have reached contractual agreement for exclusive use of a novel patented human pharmaceutical for this dermatological product and for a second application in another key therapeutic sector.

 

Species

Therapeutic Category

Target Approval

Equine

Lameness

2013

Canine

Endocrine

2014

Feline

Endocrine

2015

Feline

Gastrointestinal

2014

Canine

Dermatological

TBD

 

At maturity these products should cumulatively generate £25 million to £30 million revenue annually.

 

Generics and Unlicensed Products

A number of generic products that complement our existing range or are sold within our key therapeutic sectors are under development.  Reformulation, improvement and innovation in our unlicensed products are also ongoing.

 

Species

Therapeutic Category

Target Approval

Canine

Epilepsy

2011

Equine/Canine

Euthanasia

2012

Canine/Feline/Equine

Pain Management

2012

Canine/Feline

Pain Management

2013

Feline

Endocrine

2013

Feline

Endocrine

TBD

 

At maturity these products should cumulatively generate £4 million to £5 million revenue annually.



Pet Diets

Development of novel therapeutic pet diets continues and numerous formulation changes to improve efficacy and palatability are ongoing.  We have also signed a contract with Biomarine, a Norwegian government funded project, to research the use of bioactive peptides in the treatment and prevention of diseases in pets.  This project puts Dechra in the frontline of research into innovative ingredients for the next generation of therapeutic pet foods.

 

A novel product Specific® CED Endocrine Support is in the final stages of development.  The product is an innovative therapeutic diet to support the medical treatment of adult dogs with endocrine disorders including the treatment of diabetes and Cushing's syndrome.

 

In the autumn, a re-optimised wet food range will be introduced in flexible cans with a new design.  The maintenance wet food range will be extended with a senior wet food version (Specific CGW Senior) for dogs as well as cats (Specific FGW Senior).  The senior diets give our customers the choice to feed their pets a healthy and palatable diet which helps to prevent geriatric diseases.

 

Species

Product

Project

Target Launch Date

Canine/Feline

Senior wet diets

Completion of maintenance wet food range

2011

Canine

Endocrine

New therapeutic dry diet for endocrine support

2011

Feline

Gastrointestinal

New therapeutic dry and wet diet for gastrointestinal support

2011

Feline

Joint

New therapeutic dry and wet diet for joint support

2012

Canine/Feline

Hypo allergenic

Development of new hypo allergenic diets based on alternative protein sources

2013

Canine/Feline

Novel

Use of bioactive peptides in therapeutic diets

2014

 

European Pharmaceuticals

This segment comprises DVP EU and Dales.

 

DVP EU

What we do

This business unit markets and sells our own branded veterinary products within 13 European countries and manages the relationships with our worldwide marketing partners.

 

Operational Structure

The business has an operating board of five senior managers.  Finance, IT, pre-wholesale logistics, marketing and HR are centred in Uldum, Denmark and Hadnall, England. 

 

We have nine country managers operating out of Denmark, Finland, France, Germany, the Netherlands, Norway, Spain, Sweden and the UK.  Ireland and Portugal are managed out of the UK and Spain respectively.

 

We currently employ 73 representatives across these territories.  DVP EU employs 214 people.



Our Market

Our customers are small animal and equine veterinary surgeons, predominantly operating out of commercial veterinary practices.  European companion animal veterinary markets are currently only realising inflationary growth as footfall in most territories is declining due to the worldwide economic difficulties.  Internet pharmacies, especially in the UK, are demonstrating stronger levels of growth as consumers look to reduce the cost of pet and horse ownership.  Animal numbers in the major territories have remained static in the period being reported.  The UK is currently our largest market with approximately eight million cats, seven million dogs and one million horses.

 

Key Strengths

We are unique in having a veterinary exclusive range of products with a clear focus on companion animals and horses.  The majority of our products are novel and, on the whole, are used to treat medical conditions for which there is often no other effective solution.  Our key marketing benefit, especially on diets, is that our products are only sold to veterinary practices.

 

Achievements

Third party European marketing contracts, which were negotiated prior to the development of our own sales and marketing infrastructure, have now been terminated.  Vetoryl and Felimazole have been marketed in-house through our Nordic subsidiaries since January 2011 and have now been transferred into Dechra livery for sale through our other mainland European subsidiaries since July 2011.  We will also commence the in-house marketing of Canaural, Fuciderm Gel and Fucithalmic® Vet into Germany and Belgium and also our Specific range of pet diets into Belgium.  In Germany these products will be distributed in Dechra livery through our existing partner, Selectavet.  In Belgium we have created a new business unit which will be managed out of the Netherlands by a newly appointed Benelux manager, with sales and technical support staff being appointed within the country.  The benefit of marketing products through our own subsidiaries is a significant increase in the retained gross margin for the Group.  The full impact of this will be realised in our financial year ending 30 June 2012.

 

Following the closure last year of our pre-wholesale warehouse in Shrewsbury, England, we have relocated our UK sales, marketing, technical and regulatory teams to a new single site. This environmentally sensitive office facility provides excellent working conditions for our employees and reflects the growth and development of our pharmaceutical business.

 

Pharmaceutical sales increased by 9% in the period.

 

There were a number of product launches through our own subsidiaries and through our worldwide marketing partners:

 

·        a low dose 2.5mg Felimazole launched in the Nordics;

·        Alvegesic launched in Denmark, Sweden and France following its successful introduction into the UK last year;

·        Vetoryl launched in Japan through our partner Kyoritsu Seiyaku Corporation;

·      Fiprodog and Fiprocat®, generic flea products, were launched in the UK;

·        Rycarfa was launched just after the year end in the UK, France, Germany and Spain; and

·        preparations are being made to launch Clavudale and Urilin across the EU following their recent approvals.

 

We have successfully integrated the new products from the Genitrix and DermaPet acquisitions and are at an advanced stage of introducing them in Dechra livery.  The DermaPet range, which was previously only marketed in the UK and Nordic regions, is also being prepared for launch in other subsidiary territories.



Our Specific pet diets have outperformed the competitors in most territories in which we operate and have grown 8% over the period.  This has been achieved by our unique position of veterinary exclusivity and by keeping price increases to a minimum.  Raw material costs, however, have increased significantly over the period resulting in a margin performance slightly below last year.  The canine and majority of feline diets have been successfully transferred into a new manufacturer, resulting in improved quality and palatability.  The Feline Crystal diet, Canine Omega Support diet and Organic range, outlined under Product Development, have been successfully launched.  Following an agreement to license the formulation, brands and technical support of our Specific therapeutic diets to a US marketing and manufacturing company, the first two products were launched in June 2011.  The products are manufactured and sold by iVet under the Specific brand into the extensive American market. Dechra will receive a royalty on all sales.  The therapeutic diets have also been launched through a marketing partner in South Korea, a fast developing market.  Specific therapeutic diets are also currently being launched in the UK and a number of major practices have agreed to market the range.  This is a pleasing opening as we begin to establish the brand in this highly competitive market.

 

Dales Pharmaceuticals

What we do

Dales manufactures the vast majority of our own branded, licensed pharmaceutical products which are marketed through DVP, but also derives approximately 50% of its revenues from third party toll manufacturing, predominantly for human pharmaceutical companies.  This is Dechra's only significant source of revenue not derived from the veterinary market.

 

Operational Structure

The business has an operating board of five senior managers.  The majority of manufacturing is located in Skipton, England and employs 200 people.  There is also a small manufacturing facility in Uldum, Denmark which employs 26 people.

 

Our Market

The primary customer for Dales is DVP EU.  Our toll manufacturing customers are, in the main, small or mid sized UK based pharmaceutical companies.

 

Key Strengths

Our ability to be flexible on batch size is a major advantage, especially when introducing new pharmaceuticals.  Another key strength is our ability to produce several dosage formats such as tablets, capsules, liquids, creams, gels and powders and our ability to package these products in numerous formats.  We are also able to provide a full service for third party customers including product formulation, trial batch manufacturing, validation, production and packaging.

 

Achievements

Total overall production in the year increased by 1.2% over the corresponding period last year. However, contract manufacturing decreased by 6.5% due to a planned reduction in production by our biggest customer.  Five new contracted products were introduced with a further three products in formulation for future manufacturing for third party customers.  We have successfully transferred the manufacturing of Fuciderm and are in the process of transferring Canaural into Dales.  These key DVP products were previously outsourced.  Throughout the year we have improved our service level, increased yields, reduced waste and have therefore exceeded productivity targets.  FDA inspections have been conducted within the year and the control points raised have been remedied.  We hope to receive notification of compliance and be able to manufacture Vetoryl for the US market imminently.



US Pharmaceuticals

DVP US

What we do

DVP US markets and sells our own veterinary products across the USA.

 

Operational Structure

The business has an operating board of three senior managers, all of whom have in depth experience of the American veterinary market.  Finance, HR and pre-distributor logistics are all currently outsourced.  Our business is located in Kansas City, USA and employs 33 people, 22 of whom are field based sales representatives.

 

Our Market

Our customers are small animal and equine veterinary surgeons, predominantly operating out of commercial veterinary practices.  The USA is the world's largest veterinary market and represents a significant growth opportunity for Dechra.  Over 62% of US households own a pet which equates to 73 million homes.  Additionally, the number of pets is increasing with a current estimated population of 86 million cats, 78 million dogs and 8 million horses.

 

Key Strengths

Our key pharmaceuticals, which are the focus of the majority of our sales and marketing efforts, are unique and are the first licensed products to treat the conditions for which they are recommended.

 

Achievements

Revenue in the year was 51.5% higher than the previous year and includes the DermaPet acquisition completed in October 2010.  Underlying growth, on a like for like basis at constant currency, was 3.6%.  This strong growth has allowed us to significantly increase our infrastructure with additional marketing, operational and sales representatives being employed in the year.  Further sales and technical support staff are also currently being recruited.

 

Sales of Vetoryl, our key product, increased by 30% in the year to US$8.6 million.  Almost 13,000 veterinary clinics have purchased Vetoryl.  A report from an external audit demonstrated that Cushing's syndrome is being under diagnosed and that education and training is essential for future growth.  During the year, 56 meetings were conducted by our two technical veterinarians with almost 1,600 attendees.  We also sponsored ten meetings with external key opinion leader speakers with over 400 attendees.  We are in the process of hiring two additional field veterinarians to increase our educational programme. 

 

We continue to experience unregulated sales of Trilostane, the active principal ingredient in Vetoryl, through illegal compounding.  We have invested a significant amount of funds to lobby senators on Capitol Hill in an attempt to force the FDA to take action against compounders.  We are now looking to work with other animal health companies to continue this lobbying.

 

In December 2010 we successfully launched Equidone Gel to US equine veterinarians following its full approval by the FDA.

 

Supply issues remain with our otic and ophthalmic products from our third party suppliers, having a negative US$2 million impact on like for like sales; however, progress is being made on the transfer, validation and re-registration of these products into a new facility.  We hope to be able to re-launch the major products in 2012.



Services

This segment comprises NVS and our Laboratories, NWL and CSLS.

 

NVS

What we do

NVS is the UK market leader, as measured in terms of market share, in the supply and distribution of veterinary products to veterinary practices and other approved outlets.  NVS stock a range of over 14,000 products, including pharmaceuticals, pet products, consumables and accessories.  NVS has also developed a range of IT solutions for veterinary practices.

 

Operational Structure

The business is managed by an operating board of five experienced directors.  NVS employs 455 people across the UK, 111 of whom are delivery drivers.  

 

The centralised inventory held in Stoke-on-Trent, England is picked and packed throughout the afternoon and evening and then distributed overnight to nine trunking depots via HGVs.  Van drivers are employed locally at these depots to distribute the goods directly to our customers.  NVS has developed an advanced communication system for its customers and through this 85% of orders arrive at NVS automatically with no human input required.

 

Our Market

Our principal customers are UK veterinary practices of all types: small animal, equine, farm animal and mixed species practices.  Footfall through UK veterinary practices has declined in the year, although the overall market continues to demonstrate growth, predominantly from inflation.  The consolidation of veterinary practices into large corporate groups seen over recent years has continued within the period, putting pressure on margins and cash flow.

 

Key Strengths

NVS offers very high levels of service, a large range and depth of stock and a reliable next day national delivery service.  It also supplies a range of business solutions for veterinary practices including practice management software, benchmarking systems and marketing and business support.

 

Achievements

NVS has retained its market share above 40%; however, with growth of 3.9% over last year, we have slightly underperformed market growth relative to our competitors as we supply a smaller percentage of our sales into the higher growth food animal production and online pharmacy sectors.  These sectors offer relatively low margins.  We did, however, outperform the market in the fourth quarter with growth of 6.4%.

 

The most significant achievement in the year was the successful implementation of a new integrated IT system across the business which went live on 1 July 2011.  Very few problems were encountered and virtually no supply issues were experienced by our customers.  The second phase of implementation has now commenced, which will allow us to focus on improving management data and providing new services to customers.

 

Further cost savings as a percentage of sales were recognised in the year due to investment in new pallet picking technology and efficiencies gained by shift changes in the warehouse.  Further efficiencies will be gained as we increase the efficiency of the picking circuit and improve utilisation of our distribution system.

 

We have continued to develop our own label disposable product range, branded the Valu range.  Further development in this range is planned in the new financial year.



Our business partnership relationship with our customers has continued; new services have been launched such as mystery shopping to ascertain practices customer relationship skills, stock-taking services via vPOD, NVS Online, which personalises self-service practice data provision and we have developed strategies with practice management software suppliers to improve stock control integration and efficiencies within veterinary practices.

 

Laboratories

What we do

NWL is a first referral veterinary laboratory.  We provide histology, pathology, haematology, chemistry and microbiology services to veterinary practices.  CSLS provides secondary referral services with our key area of expertise being endocrinology.  CSLS also provides precise assays which support the dosage regimes and patient monitoring of DVP's key products, Vetoryl and Felimazole.

 

Operational Structure

The Laboratories, employing 75 people, are run by an operational board of three senior managers and are supported by the Group Financial Controller who also sits on this board.  NWL is located in Poulton-le-Fylde, Leeds and Swanscombe, and CSLS is located in Sawston, England.  Samples are received on a daily basis via post, couriers and our own collection service.  Where the science allows, a same day or next day results service is provided. 

 

Our Market

NWL's customers are UK commercial veterinary practices.  We have historically provided support to companion animal practices; however, in the last two years we have introduced an increased range of large animal and equine services.  CSLS provides some first level support similar to NWL to UK veterinary practices; however, their major area of specialisation is in very precise endocrine assays which it supplies directly to veterinary practices and other first referral laboratories.

 

Key Strengths

We offer a high quality service with a very experienced team of veterinary pathologists who provide a fully interpreted results service on all samples received.

 

Achievements

It has been a very difficult year for laboratory services.  As expected, expensive diagnostic procedures have reduced significantly due to lower footfall through veterinary practices.  We have, however, recently launched the FUJI Film Dry Chemistry Analyser which is a system that allows simple diagnostic testing of blood within veterinary practices.  During the year, we have 24 analysers placed in practice.  The main revenue driver is the repeat orders of disposable test slides which are used within the machines.

 

Information Technology

Major changes and improvements in the Group's technology capabilities have been implemented in the period.

 

Drug Monitoring

During the period, the Regulatory team have implemented an electronic pharmaceutical monitoring and reporting system which can communicate adverse reactions electronically to the FDA in the USA.

 

ERP Systems

NVS, our veterinary distributor, successfully implemented a new ERP system provided by IFS on 1 July 2011.  The new system will provide enhanced management information, improve the interface with other Group reporting systems and create operational flexibility upon which we can develop new services.



An Oracle system was implemented at our UK manufacturing business, Dales, two years ago.  This was also successfully implemented at our Danish manufacturing site in November 2010.  A programme has commenced to roll out Oracle across the entirety of our European Pharmaceutical segment businesses and eventually into DVP US.

 

Our Laboratories have identified a new IT system, Autoscribe, which is targeted to be implemented within the current calendar year.

 

Customer Solutions and Ordering Platform

We currently market two veterinary practice management systems through our veterinary distributor, NVSVetcom® Open, our most advanced system which is developed through a partnership agreement, has made significant programming and functionality advancements and now has competitive benefits over other market leading systems.  Vetcom Windows, our in-house developed introductory practice management system, has also been modernised and developed ready for re-launch.  Work has now commenced on updating vPOD, our hand-held stock control and ordering terminal, to allow it to operate on android hardware.

 

NVS has also updated Indices, a system which allows our veterinary customers to benchmark their performance against comparable practices on both a regional and national basis.  The new system is faster and easier to use and has significantly enhanced functionality allowing veterinary practices greater access to business information.

 

Communication Tools

Within Dechra Veterinary Products we have continued to invest in state of the art online communication tools.  We are one of the leading companies within the veterinary industry to offer educational webinars. Since inception we have conducted six online webinars in the UK with over 1,000 attendees and four in the US with over 500 attendees.

 

In addition to webinars we offer online continued professional development courses branded the Dechra Academy. We have approximately 9,000 registrations from veterinarians and veterinary nurses for this educational programme.

 

Our Dechra Veterinary Product websites are constantly being updated with technical and clinical information. All of the Genitrix and DermaPet products have now been integrated onto the DVP EU and US websites.  We are also currently updating this site into other languages.  The German site launch is imminent; the French and Spanish translations are in progress.

 

An e-newsletter is now distributed monthly to over 7,000 veterinary professionals within the UK.  This medium is used to provide up-to-date product and Dechra Academy information.

 

HR

The Group HR Director, supported by a steering group of senior managers, has defined the principles of standards and behaviour to achieve and promote a high performance culture.  These criteria have become known as the Dechra Values.  The steering group has also developed a performance management mechanism incorporating the Dechra Values which will be used annually to review employees and provide a basis for future reward and development.



Key Performance Indicators ("KPIs")

Financial

Method of Calculation

Target

2011 Performance

Five Year Record

 

Revenue from key pharmaceutical products

Global revenue from our top five products

To achieve annual revenue growth of at least 10%

The KPI was exceeded during the year with a growth rate of 12.8% being achieved.  Vetoryl and Felimazole grew particularly strongly

11 £33.2m

10 £29.4m

09 £23.6m

08 £15.3m*

07 £10.6m*

* Canaural and Fuciderm acquired in January 2008

 

Revenue from specialist pet diets

Global revenue from the Specific brand of pet diets

To achieve annual revenue growth of at least 6%

Despite increasingly competitive markets a growth rate of 8.1% was achieved

11 £27.6m

10 £25.6m

09 £22.7m

08 £9.9m*

07 n/a*

* Diets range acquired in January 2008

 

Underlying operating margin before product development cost

Underlying operating profit before product development expenditure expressed as a percentage of Group revenue

To achieve an underlying operating margin before product development costs of 10% in the medium term

Further progress towards the medium term target was made with the increased operating margin from our US business making a strong contribution

 

11 9.5%

10 8.9%

09 8.1%

08 7.1%

07 6.1%

 

Cash conversion rate

Cash generated from operations before tax and interest payments as a percentage of operating profit before amortisation of acquired intangibles

To achieve an annual cash conversion rate of at least 100%

The target rate of 100% has not been achieved this year principally due to additional payment terms being offered to certain large NVS customers

 

11 82.8%

10 100.8%

09 112.5%

08 94.2%

07 103.3%

 

Return on capital employed ("ROCE")

Underlying operating profit as a percentage of average operating assets utilised.  Operating assets exclude cash and cash equivalents, borrowings, tax and deferred tax balances

To achieve a return on capital employed which exceeds the pre-tax weighted average cost of capital of the Group ("WACC")

Although ROCE fell slightly in 2011 due to the acquisitions made in the period the figure is still well ahead of the WACC of the Group

11 21.6%

10 22.6%

09 19.4%

08 23.3%

07 37.5%

 



 

Non-Financial

Method of Calculation

Target

2011 Performance

Five Year Record

 

Pharmaceutical product development pipeline

Number of products from the pipeline or in-licensed into at least one major territory with long term revenue potential of at least £0.5 million

One new diet or range extension launched in the EU, two new pharmaceuticals, each launched in at least one key market

 

Three novel diets launched and three pharmaceutical products launched within the EU

11 6 products

10 6 products

09 5 products

08 3 products

07 3 products

 

Health and safety performance

Lost Time Accident Frequency Rate ("LTAFR"): all accidents resulting in absence or the inability of employees to conduct the full range of their normal working activities for a period of more than three working days after the day when the incident occurred normalised per 100,000 hours worked

 

Zero preventable accidents

There has been an increase in the total number of accidents during the year from 14 to 15. None of these accidents have resulted in a work related fatality or disability.

 

11 0.82

10 0.75

09 0.94

08 n/a*

07 n/a*

* Information not collected for these years

Employees

Employee turnover calculated as number of leavers during the period as a percentage of the average total number of employees in the period

Moving Annual Turnover ("MAT") rate of less than 15%

The MAT increased from last year's 15.88% to 19.03%.  A reorganisation within our NVS warehouse and a higher than normal number (21) of retirements has contributed to this year's MAT target not being met.

11 19.03%

10 15.88%

09 19.81%

08 29.7%

07 n/a*

* Information not collected for these years



Dechra Pharmaceuticals PLC

Preliminary Results for the year ended 30 June 2011

 

FINANCIAL REVIEW BY THE GROUP FINANCE DIRECTOR, SIMON EVANS

 

Group Performance

Financial Highlights

Underlying Results

Reported Results


2011

2010

Change

2011

2010

Change


£'000

£'000

%

£'000

£'000

%

 

Revenue

389,237

369,369

5.4

389,237

369,369

5.4

Gross profit

88,361

80,625

9.6

88,361

80,625

9.6

% of revenue

22.7%

21.8%


22.7%

21.8%


Distribution costs

(17,659)

(16,242)

(8.7)

(17,659)

(16,542)

(6.8)

Selling, general and

 administrative expenses

 

(33,658)

 

(31,527)

 

(6.8)

 

(43,763)

 

(39,551)

 

(10.6)

Research and

 development expenses

 

(5,221)

 

(4,666)

 

(11.9)

 

(5,221)

 

(4,666)

 

(11.9)

Operating profit

31,823

28,190

12.9

21,718

19,866

9.3

% of revenue

8.2%

7.6%


5.6%

5.4%


Profit before taxation

30,069

26,056

15.4

18,514

17,732

4.4

Taxation

(7,321)

(6,619)


(4,380)

(4,575)


Profit after tax

22,748

19,437


14,134

13,157


Earnings per share

34.33p

29.50p

16.4

21.33p

19.97p

6.8

Operating cash flow

 before interest and tax

 payments

 

 

25,374

 

 

26,662

 

 

(4.8)

 

 

25,374

 

 

26,662

 

 

(4.8)

Cash conversion rate

82.8%

100.8%


82.8%

100.8%


Free cash flow

9,294

9,938

(6.5)

9,294

9,938

(6.5)

Tax rate

24.3%

25.4%


23.7%

25.8%


Total dividend per share

12.10p

10.50p

15.2

12.10p

10.50p

15.2

Net borrowings

34,091

6,701


34,091

6,701


 

Analysis of Revenue and Underlying Operating Profit Growth


Revenue

Underlying

Operating Profit


£'000

%

£'000

%

 

Year ended 30 June 2010

369,369


28,190


Organic growth at constant currency

14,574

3.9

1,194

4.2

Impact of acquisitions

6,558

1.8

2,722

9.7

Impact of foreign currency movements

(1,264)

(0.3)

(283)

(1.0)

Year ended 30 June 2011

389,237

5.4

31,823

12.9



Revenue


Change


%

 

European Pharmaceuticals


Own branded pharmaceuticals

8.8

Diets

8.1

Third party contract manufacturing

(6.5)

Instruments, consumables and equipment

2,280

2,859

(20.3)

Total European Pharmaceuticals

89,287

84,637

5.5

US Pharmaceuticals

51.5

Services


Veterinary wholesaling

3.9

Laboratories

5,078

5,285

(3.9)

Total Services

296,258

285,670

3.7

Inter-segment

(12,415)

(11,572)


Total revenue

389,237

369,369

5.4

 

Group revenue increased by 5.4% compared to last year.  During the year the Group acquired DermaPet Inc., based in Florida, and Genitrix Limited, based in the UK.  These two acquisitions contributed 1.8% of growth in revenue.  Currency fluctuations had a negative impact on revenue of 0.3%.

 

Within the European Pharmaceuticals segment, own branded pharmaceuticals performed robustly with most of our key brands showing solid growth.  As disclosed in the KPI table, our leading five brands achieved growth of 12.8% compared to last year.

 

Diets revenues grew by 8.1% overall.  Some pressure on revenue was experienced in the second half of the financial year as economic conditions in a number of European countries weakened.

 

As expected, contract manufacturing revenues were 6.5% lower than last year due to a planned reduction in production for our biggest single third party contract.  However total production levels increased due to higher volumes of our own products.

 

Revenue from US Pharmaceuticals grew by 51.5% in the year with the biggest single contributor being the DermaPet product lines which were acquired in October 2010.  Vetoryl also achieved good growth whilst there was an initial contribution from Equidone, our equine product launched in December 2010.  As, previously reported, issues with a third party supplier meant that sales of our ophthalmic and otic ranges were approximately US$2 million lower than the previous year.

 

Within our Services segment, our UK veterinary wholesaler, NVS, achieved revenue growth of 3.9% in the financial year with some acceleration of this growth rate achieved in the fourth quarter.  Revenue from our Laboratories business was down by 3.9% reflecting the difficult market.

 

Gross Profit

Gross profit for the Group was up by 9.6% from £80.6 million to £88.4 million with the gross margin increasing by 90 basis points.  This was predominantly driven by increased revenue from higher margin pharmaceuticals.  Diets gross margin fell slightly as raw material costs and currency impacted results.  The gross margin achieved by our wholesaler, NVS, was broadly stable compared to last year.

 

Underlying Distribution Costs

Distribution costs increased by 8.7% from £16.2 million to £17.7 million.  As well as increased volumes, the main factor in this increase was fuel costs, which was mitigated by efficiency savings.



Underlying Selling, General and Administrative ("SG&A") Expenses

Underlying SG&A expenses increased by 6.8% compared to 2010.  The majority of this increase occurred in our US business as a result of further investment in sales people to support the DermaPet products and in line with our growth strategy.

 

Research and Development Expenses

Research and development expenditure was up by 11.9% from £4.7 million to £5.2 million.  This increased expenditure supports our product development programme.

 

Underlying Operating Profit






2011

2010

Change


£'000

£'000

%

 

European Pharmaceuticals

22,506

21,412

5.1

US Pharmaceuticals

4,838

1,311

269.0

Services

13,087

13,103

(0.1)

Research and development

(5,221)

(4,666)

(11.9)

Central costs

(3,387)

(2,970)

(14.0)

Underlying operating profit

31,823

28,190

12.9

 

Underlying operating profit of European Pharmaceuticals rose by 5.1% during the year (6.5% at constant currency).  The main driver of this increase was the performance of our own branded pharmaceuticals although the improvement in profit was constrained by a lower diets gross margin and reduced contract manufacturing revenues.

 

Our US business's underlying operating profit grew by 269.0% with the acquisition of DermaPet making a major contribution to this result.  The strong increase in Vetoryl revenues also contributed.

 

Within Services, NVS achieved an increase in operating profit with operating margin being maintained.  This was offset by a significant reduction in the profitability of the Laboratories with the reduction in revenue having an amplified impact on the bottom line.

 

Underlying Net Finance Expense

Underlying net finance expense was £1.8 million compared to £2.1 million in 2010.  The net finance expense benefited from a £1.0 million gain on foreign exchange (2010: £0.2 million gain), although this was partially offset by interest on additional borrowings to fund the acquisitions of DermaPet and Genitrix.

 

Underlying Profit Before Taxation

Underlying profit before taxation rose from £26.1 million to £30.1 million, an increase of 15.4%.

 

Non-underlying Items

Non-underlying items in the year comprised amortisation of intangibles acquired as a result of business combinations together with one off costs related to the acquisitions of DermaPet and Genitrix including the resulting refinancing.  The Directors believe that highlighting these items separately gives a better understanding of the performance of the Group.

 

Taxation

The effective tax rate on underlying earnings was 24.3% (2010: 25.4%). This included a credit of £0.4 million (2010: £0.1 million) in respect of prior years.  Going forward, the Group will benefit from the planned reductions in the UK corporation tax rate.



Earnings per Share and Dividend

Underlying earnings per share increased by 16.4% from 29.50 pence to 34.33 pence, the fifth successive year of double digit growth.

 

The Board is proposing a final dividend of 8.40 pence per share which, when added to the interim dividend of 3.70 pence per share already paid, gives a total dividend for the year of 12.10 pence compared to 10.50 pence in 2010.

 

The total dividend is covered 2.6 times (2010: 2.6 times) by profit after taxation after adding back amortisation of acquired intangibles.

 

Cash Flow


2010


£'000

 

EBITDA

29,283

Share-based payments charge

817

Changes in working capital

(9,071)

(3,438)

Cash generated from operations

26,662

Net interest

(2,208)

Taxes paid

(6,124)

Capital expenditure

(2,721)

Proceeds of asset sales

-

Repayment of borrowings

(4,329)

(5,671)

Free cash flow

9,938

Acquisitions

-

Net new borrowings

-

Issue of share capital

589

Dividends

(6,195)

Foreign currency effects

(129)

353

Net cash flow

(1,006)

4,685

 

The cash conversion rate in 2011 was 82.8% (2010: 100.8%) with the reduction due principally to additional payment terms being offered to certain large NVS customers.

 

Financial Position at the Year End


2011

2010


£'000

£'000

 

Non-current assets



Intangible assets

125,098

80,371

Property, plant and equipment

7,721

7,673


132,819

88,044

Working capital

32,494

21,486

Deferred and contingent consideration

(14,055)

-

Current tax liability

(5,391)

(4,105)

Deferred tax liability

(13,443)

(12,496)

Net borrowings

(34,091)

(6,701)

Net assets

98,333

86,228

 

Intangible assets and net borrowings increased compared to last year due to the two acquisitions made during the period. The balance sheet remains strong with net borrowings having reduced by £15.6 million since 31 December 2010. The net borrowings at 30 June 2011 of £34.1 million are comfortably affordable, representing only 0.98 times underlying EBITDA.



Of the increase in working capital, £1.5 million was as a result of the acquisitions.  Inventory levels were increased in the first half of the financial year to ensure continuity of supply during the transfer of our diet range to a new manufacturer.  This was partially reversed in the second half.  The remaining increase was due to higher revenues and additional payment terms that NVS offered to a major customer.

 

Bank Facilities

Our bank facilities were refinanced during the year in order to fund the acquisition of DermaPet.  The new facilities run through to 2014.  There was substantial headroom on all covenants during the year.

 

Risks and Uncertainties

As we have stated in previous reports, the Group, like every business, faces risks and uncertainties in both its day-to-day operations and through events relating to the achievement of its long term strategic objectives.  The Board has ultimate responsibility for risk management within the Group and there is an ongoing and embedded process of assessing, monitoring, managing and reporting on significant risks faced by the separate business units and by the Group as a whole.

 

The table on the following page highlights the main potential risks to the Group strategy, as identified by the Board, and the controls put in place in order to mitigate the said risks:



The main potential risk areas identified by the Board are as follows:

 

Strategy

 

Risk

How we mitigate the risk

To sustain growth from our core businesses

The failure of a major customer or supplier

·        The business units monitor the financial status of both key customers and suppliers and maintain regular contact with them (including face to face meetings)

·        Where it becomes evident that issues in relation to manufacturing/supply may arise alternative suppliers are identified and detailed plans drafted.  Where a manufacturing transfer is required stock is built up in order to avoid/mitigate an out of stock situation

·        In respect of manufacturing, a "second sourcing" project for key materials has been established and maintained

·        All contracts with suppliers and customers are reviewed from both a commercial and legal perspective to ensure that assignment of the contract is allowed should there be a change of control of either of the contracting parties


Failure to meet regulatory requirements under which we operate thereby disrupting our operations and our product manufacture pipeline/loss of key products due to regulatory changes

·        The Group always strives to exceed regulatory requirements and ensures that its employees have detailed experience and knowledge of the regulations

·        All businesses have clearly established quality systems and procedures in place

·        Regular contact is maintained with all relevant regulatory bodies in order to build/strengthen relationships and ensure good communication lines

·        The regulatory and legal teams remain constantly updated in respect of proposed/actual changes in order to ensure that the business is equipped to deal with and adhere to such changes

·        Where any changes are identified which could affect our ability to continue to market and sell any of our products a response team is created in order to mitigate such risk and to retain effective communication with the relevant regulators

·        External consultants are utilised to audit our manufacturing systems prior to any major inspection


Loss of key personnel

·        Succession planning is given consideration by the Board and, where deemed necessary, Key Man Insurance is in place

·        In 2009 the Group HR director developed and implemented a leadership development program for the senior management team in order to further strengthen the retention of the individuals.  This program is ongoing and includes the involvement of personal coaches

·        A Performance and Development Review process is in the early stages of implementation


Fuel shortage/logistics failure

·        Standard operating procedures have been drafted in respect of fuel emergencies/failures of the courier company (the latter in respect of the Laboratories only) to provide a daily service.  Such standard operating procedures are regularly reviewed in order to ensure they remain effective

·        Delivery routes are constantly monitored by the operations department in order to ensure that they remain effective, economic and efficient

·        Routine ongoing maintenance of the automated picking circuit at NVS and ensuring that all critical components are held on site

To continue to develop a high growth, cash generative specialist veterinary products business

Competitor product launched against one of our leading brands

·        Product improvement plans and marketing strategies are reviewed on a regular basis

·        Where competitor products are launched a response strategy is established and followed by our marketing team to highlight any unique selling points or competitive advantages or to position our products defensively to minimise competitor impact

·        Market research is conducted in order to allow the marketing team to better understand customer needs and ensure that our products fulfil the identified requirements

·        Any product patents are monitored and consideration given to the formulation of a defensive strategy towards the end of the life of the patent


Revenue from recently launched new products failing to meet expectations

·        In respect of all new product launches a detailed marketing plan is established.  Progress against the plan is constantly monitored

·        The Group ensures that it has detailed market knowledge and retains close contact with customers through its sales teams which are consistently trained to a high standard

·        Alongside the marketing plan the sales team receives training on the product, its benefits and all available technical information


Failure of clinical trials

·      Before major costly efficacy studies are initiated, smaller proof of concept studies are conducted to study the effects of the drug on target species and for the target indication


Consolidated Income Statement

for the year ended 30 June 2011

 



2011

2010



 

 

 

Underlying

£'000

Non-

underlying

items*

(notes 4 & 5)

£'000

 

 

 

Total

£'000

 

 

 

Underlying

£'000

Non-

underlying

items*

(note 5)

£'000

 

 

 

Total

£'000

 


Note







 

Revenue

 

2

 

389,237

 

-

 

389,237

 

369,369

 

-

 

369,369

Cost of sales


(300,876)

-

(300,876)

(288,744)

-

(288,744)

 

Gross profit


 

88,361

 

-

 

88,361

 

80,625

 

-

 

80,625

Distribution costs


(17,659)

-

(17,659)

(16,242)

(300)

(16,542)

Administrative expenses


(38,879)

(10,105)

(48,984)

(36,193)

(8,024)

(44,217)

 

Operating profit

 

2

 

31,823

 

(10,105)

 

21,718

 

28,190

 

(8,324)

 

19,866

Finance income

3

2,144

-

2,144

1,632

-

1,632

Finance expense

4

(3,898)

(1,450)

(5,348)

(3,766)

-

(3,766)

 

Profit before taxation


 

30,069

 

(11,555)

 

18,514

 

26,056

 

(8,324)

 

17,732

Income tax expense

6

(7,321)

2,941

(4,380)

(6,619)

2,044

(4,575)

 

Profit for the year

 attributable to owners

 of the parent


 

 

 

22,748

 

 

 

(8,614)

 

 

 

14,134

 

 

 

19,437

 

 

 

(6,280)

 

 

 

13,157

 

Earnings per share








Basic

8



21.33p



19.97p

 

Diluted

 

8



 

21.26p



 

19.89p

 

Dividend per share

 (interim paid and final

 proposed for the year)

 

 

 

7



 

 

 

12.10p



 

 

 

10.50p

 

* Non-underlying items comprise amortisation of acquired intangibles, acquisition expenses, rationalisation costs, payments to acquire technology for the research and development programme, impairment charges, loss on extinguishment of debt and the unwinding of discounts on deferred and contingent consideration



Consolidated Statement of Comprehensive Income

for the year ended 30 June 2011

 


2011

£'000

2010

£'000

 

Profit for the period

14,134

13,157

 

Other comprehensive income:



Effective portion of changes in fair value of cash flow hedges

(684)

593

Cash flow hedges recycled to income statement

670

-

Foreign currency translation differences for foreign operations

3,411

(1,949)

Net loss on hedge of net investment in foreign operations

-

(1,300)

Recycled to income statement

-

(512)

Income tax relating to components of other comprehensive income

(4)

249

Total comprehensive income for the period attributable to owners of the parent

17,527

10,238



Consolidated Statement of Financial Position

at 30 June 2011

 


 

 

Note

2011

£'000

2010

£'000

 

ASSETS

 




Non-current assets




Intangible assets

9

125,098

80,371

Property, plant & equipment

10

7,721

7,673

 

Total non-current assets


 

132,819

 

88,044

 

Current assets




Inventories

12

40,760

34,819

Trade and other receivables

13

66,293

51,162

Cash and cash equivalents

14

30,496

31,502

 

Total current assets


 

137,549

 

117,483

 

Total assets


 

270,368

 

205,527

 

LIABILITIES




 

Current liabilities




Borrowings

17

(8,502)

(20,441)

Trade and other payables

15

(74,559)

(64,495)

Deferred and contingent consideration


(500)

-

Current tax liabilities

16

(5,391)

(4,105)

 

Total current liabilities


 

(88,952)

 

(89,041)

 

Non-current liabilities




Borrowings

17

(56,085)

(17,762)

Deferred and contingent consideration


(13,555)

-

Deferred tax liabilities

11

(13,443)

(12,496)

 

Total non-current liabilities


 

(83,083)

 

(30,258)

 

Total liabilities


 

(172,035)

 

(119,299)

 

Net assets


 

98,333

 

86,228

 

EQUITY




Issued share capital

18

664

661

Share premium account


63,559

63,021

Hedging reserve


(294)

(276)

Foreign currency translation reserve


4,751

1,340

Merger reserve


1,770

1,770

Retained earnings


27,883

19,712

 

Total equity attributable to equity holders of the parent


 

98,333

 

86,228



Consolidated Statement of Changes in Shareholders' Equity

for the year ended 30 June 2011

 


Attributable to owners of the parent

 

 

 

 

Year ended 30 June 2010

 

 

Issued

Share

capital

£'000

 

Share

premium

account

£'000

 

 

Hedging

reserve

£'000

Foreign

currency

translation

reserve

£'000

 

 

Merger

reserve

£'000

 

 

Retained

earnings

£'000

 

 

 

Total

£'000

 

 

 








At 1 July 2009

656

62,437

(703)

4,686

1,770

11,840

80,686

Profit for the period

-

-

-

-

13,157

13,157

Effective portion of changes in fair value of

 cash flow hedges, net of tax

 

-

 

-

 

427

 

-

 

-

 

-

 

427

Foreign currency translation differences for

 foreign operations, net of tax

 

-

 

-

 

-

 

(2,041)

 

-

 

-

 

(2,041)

Net loss on hedge of net investment in

 foreign operations, net of tax

 

-

 

-

 

-

 

(936)

 

-

 

-

 

(936)

Cash flow hedges recycled to income

 statement, net of tax

 

-

 

-

 

-

 

(369)

 

-

 

-

 

(369)

 

Total comprehensive income

 

-

 

-

 

427

 

(3,346)

 

-

 

13,157

 

10,238

Transactions with owners







Dividends paid

-

-

-

-

-

(6,195)

(6,195)

Share-based payments

-

-

-

-

-

910

910

Shares issued

5

584

-

-

-

-

589

Total contributions by and distributions to

 owners

 

5

 

584

 

-

 

-

 

-

 

(5,285)

 

(4,696)

 

At 30 June 2010

 

661

 

63,021

 

(276)

 

1,340

 

1,770

 

19,712

 

86,228

 

Year ended 30 June 2011

 







At 1 July 2010

661

63,021

(276)

1,340

1,770

19,712

86,228

Profit for the period

-

-

-

-

14,134

14,134

Effective portion of changes in fair value of

 cash flow hedges, net of tax

 

-

 

-

 

(506)

 

-

 

-

 

-

 

(506)

Foreign currency translation differences for

 foreign operations, net of tax

 

-

 

-

 

-

 

3,411

 

-

 

-

 

3,411

Cash flow hedges recycled to income

 statement, net of tax

 

-

 

-

 

488

 

-

 

-

 

-

 

488

 

Total comprehensive income

 

-

 

-

 

(18)

 

3,411

 

-

 

14,134

 

17,527

Transactions with owners







Dividends paid

-

-

-

-

-

(7,221)

(7,221)

Share-based payments

-

-

-

-

-

1,258

1,258

Shares issued

3

538

-

-

-

-

541

Total contributions by and distributions to

 owners

 

3

 

538

 

-

 

-

 

-

 

(5,963)

 

(5,422)

 

At 30 June 2011

 

664

 

63,559

 

(294)

 

4,751

 

1,770

 

27,883

 

98,333

 

Hedging Reserve

The hedging reserve represents the cumulative fair value gains or losses on derivative financial instruments for which cash flow hedge accounting has been applied.

 

Foreign Currency Translation Reserve

The foreign currency translation reserve contains exchange differences on the translation of subsidiaries with a functional currency other than Sterling and exchange gains or losses on the translation of liabilities that hedge the Company's net investment in foreign subsidiaries.

 

Merger Reserve

The merger reserve represents the excess of fair value over nominal value of shares issued in consideration for the acquisition of subsidiaries where statutory merger relief has been applied in the financial statements of the Parent Company.



Consolidated Statement of Cash Flows

for the year ended 30 June 2011

 


 

 

Note

2011

£'000

2010

£'000

 

Cash flows from operating activities




Profit for the period


14,134

13,157

Adjustments for:




Depreciation


1,535

1,509

Amortisation and impairment


10,362

7,908

Loss on sale of property, plant and equipment


1

-

Finance income


(2,144)

(1,632)

Finance expense


5,348

3,766

Equity-settled share-based payment expense


830

817

Income tax expense


4,380

4,575

Operating cash flow before changes in working capital


34,446

30,100

Increase in inventories


(4,814)

(3,126)

Increase in trade and other receivables


(12,408)

(3,833)

Increase in trade and other payables


8,150

3,521

Cash generated from operating activities before interest and

 taxation


 

25,374

 

26,662

Interest paid


(3,586)

(3,214)

Income taxes paid


(5,034)

(6,124)

Net cash inflow from operating activities


16,754

17,324

Cash flows from investing activities




Proceeds from sale of property, plant and equipment


2

-

Interest received


957

1,006

Acquisition of subsidiaries


(33,047)

-

Purchase of property, plant and equipment


(1,280)

(1,243)

Capitalised development expenditure


(1,025)

(955)

Purchase of other intangible non-current assets


(1,785)

(523)

Net cash outflow from investing activities


(36,178)

(1,715)

Cash flows from financing activities




Proceeds from the issue of share capital


541

589

New borrowings


68,000

-

Expenses of raising new borrowings


(944)

-

Repayment of borrowings


(41,829)

(5,671)

Resetting of foreign currency borrowings


320

456

Dividends paid


(7,221)

(6,195)

Net cash inflow/(outflow) from financing activities


18,867

(10,821)

Net (decrease)/increase in cash and cash equivalents


(557)

4,788

Cash and cash equivalents at start of period


31,502

26,817

Exchange differences on cash and cash equivalents


(449)

(103)

Cash and cash equivalents at end of period


30,496

31,502

Reconciliation of net cash flow to movement in net borrowings




Net (decrease)/increase in cash and cash equivalents


(557)

4,788

Repayment of borrowings


41,829

5,671

New borrowings


(68,000)

-

Expenses of raising new borrowings


944

-

Exchange differences on cash and cash equivalents


(449)

(103)

Retranslation of foreign borrowings


254

(1,230)

Other non-cash changes


(1,411)

(300)

Movement in net borrowings in the period


(27,390)

8,826

Net borrowings at start of period


(6,701)

(15,527)

Net borrowings at end of period

20

(34,091)

(6,701)



Notes to the Preliminary Results

for the year ended 30 June 2011

 

1.         Status of Accounts

The summary financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union ("adopted IFRS").  These summary financial statements have also been prepared in accordance with the Companies Act 2006.

 

The Board of Directors approved the preliminary announcement on 6 September 2011.

 

2.         Operating Segments

The Group has four reportable segments, as discussed below, which are based on information provided to the Board of Directors, which is deemed to be the Group's chief operating decision maker.  Several operating segments which have similar economic characteristics have been aggregated into the reporting segments.

 

The Services segment comprises National Veterinary Services, NationWide Laboratories and Cambridge Specialist Laboratory Services.  The segment services UK veterinary practices in both the companion animal and livestock sectors.

 

The European Pharmaceuticals segment comprises Dechra Veterinary Products EU and Dales Pharmaceuticals. Dales manufactures the vast majority of own branded licensed pharmaceutical products, which are marketed through DVP EU.  The segment operates internationally and is unique in having its sole area of specialisation in companion animal products.

 

The US Pharmaceuticals segment consists of Dechra Veterinary Products US which sells companion animal pharmaceuticals into that territory.

 

The Pharmaceuticals research and development segment includes all of the Group's pharmaceutical research and development activities.

 

There are varying levels of intersegment trading.  Intersegment pricing is determined on an arm's length basis.



Reconciliations of reportable segment revenues, profit or loss and liabilities and other material items:

 


2011

£'000

2010

£'000

 

Revenue by segment



Services

- total

296,258

285,670


- intersegment

(190)

(195)

European Pharmaceuticals

- total

89,287

84,637


- intersegment

(12,225)

(11,377)

US Pharmaceuticals

16,107

10,634


389,237

369,369

Operating profit/(loss) by segment



Services

13,087

13,103

European Pharmaceuticals

22,506

21,412

US Pharmaceuticals

4,838

1,311

Pharmaceuticals research and development

(5,221)

(4,666)

Segment operating profit

35,210

31,160

Corporate and other unallocated costs

(3,387)

(2,970)

Underlying operating profit

31,823

28,190

Amortisation of acquired intangibles

(8,938)

(6,580)

Rationalisation costs

(474)

(1,096)

Acquisition costs

(693)

-

Impairment of intangible asset

-

(230)

Payment to acquire technology for research and development programme

-

(418)

Total operating profit

21,718

19,866

Finance income

2,144

1,632

Finance expense

(5,348)

(3,766)

Profit before taxation

18,514

17,732

Total liabilities by segment



Services

(58,337)

(51,386)

European Pharmaceuticals

(14,465)

(11,954)

US Pharmaceuticals

(13,837)

(557)

Pharmaceuticals research and development

(654)

(567)

Segment liabilities

(87,293)

(64,464)

Corporate loans and revolving credit facility

(63,814)

(37,156)

Corporate accruals and other payables

(2,094)

(1,078)

Current and deferred tax liabilities

(18,834)

(16,601)


(172,035)

(119,299)

Additions to intangible non-current assets by segment



Services

158

136

European Pharmaceuticals

8,244

497

US Pharmaceuticals

40,056

-

Pharmaceuticals research and development

1,212

845


49,670

1,478



 


2011

£'000

2010

£'000

 

Additions to Property, Plant and Equipment by segment



Services

280

142

European Pharmaceuticals

874

813

US Pharmaceuticals

63

288

Pharmaceuticals research and development

86

-


1,303

1,243

Depreciation and amortisation by segment



Services

438

448

European Pharmaceuticals

9,091

8,251

US Pharmaceuticals

1,961

182

Pharmaceuticals research and development

407

306


11,897

9,187

 

Geographical Information

The following table shows revenue based on the geographical location of customers:

 


 

2011

Revenue

£'000

2011

Non-current

assets

£'000

 

2010

Revenue

£'000

2010

Non-current

assets

£'000

 

UK

305,737

29,156

305,992

20,981

Rest of Europe

56,452

66,954

49,451

67,033

USA

16,107

36,709

10,634

30

Rest of world

10,941

-

3,292

-


389,237

132,819

369,369

88,044

 

No customer accounted for more than 10% of total Group revenues.

 

3.         Finance Income


2011

£'000

2010

£'000

 

Recognised in profit or loss



Finance income arising from:



- Cash and cash equivalents

1,113

894

- Loans and receivables

32

112

- Foreign exchange gains

999

626


2,144

1,632

 

4.         Finance Expense

 

 

Underlying

2011

£'000

2010

£'000

 

Finance expense arising from:



- Financial liabilities at amortised cost

3,898

3,365

- Derivatives at fair value through profit or loss

-

401

Underlying finance expense

3,898

3,766

 

Non-underlying



Loss on extinguishment of debt

1,256

-

Unwinding of discounts on deferred and contingent consideration

194

-

Non-underlying finance expense

1,450

-

Total finance expense

5,348

3,766



5.         Non-Underlying Items

Non-underlying items comprise:

 

 

2011

£'000

2010

£'000

 

Amortisation of intangible assets acquired as a result of business

 combinations

 

8,938

 

6,580

Rationalisation costs

474

1,096

Expenses of the acquisition of DermaPet Inc.

585

-

Expenses of the acquisition of Genitrix Limited

108

-

Payment to acquire technology for research and development

 programme

 

-

 

418

Impairment of intangible asset

-

230


10,105

8,324

 

Rationalisation costs in 2011 relate to the integration of DermaPet Inc. and Genitrix Limited.

 

Rationalisation costs in 2010 relate to the closure of our pharmaceutical warehouse in Shrewsbury and transfer of all pre-wholesale logistics to our facility in Uldum, Denmark.

 

6.         Income Tax Expense


2011

£'000

2010

£'000

 

Current tax

- UK corporation tax

4,551

3,678


- overseas tax at prevailing local rates

2,134

2,626


- adjustment in respect of prior years

(728)

(92)

Total current tax expense

5,957

6,212

 

Deferred tax

 

- origination and reversal of temporary differences

 

(1,874)

 

(1,637)


- adjustment in respect of prior years

297

-

Total deferred tax expense

(1,577)

(1,637)

Total income tax expense in the income statement

4,380

4,575

 

The tax on the Group's profit before tax differs from the standard rate of UK corporation tax of 27.5% (2010: 28%).  The differences are explained below:


2011

£'000

2010

£'000

 

Profit before taxation

18,514

17,732

Tax at 27.5% (2010: 28%)

5,091

4,965

Effect of:



- depreciation on assets not eligible for tax allowances

8

8

- disallowable expenses

450

48

- (over)/under-recovery of deferred tax on share-based payments

(28)

40

- research and development tax credits

(50)

(60)

- differences on overseas tax rates

(165)

(334)

- adjustments in respect of prior years

(431)

(92)

- non-taxable income

(495)

-

Total income tax expense

4,380

4,575



 

 

Tax Recognised Directly in Equity

2011

£'000

2010

£'000

 

Deferred tax on effective portion of changes in fair value of cash

 flow hedges

 

(4)

 

(166)

Corporation tax on net loss on hedge of net investment in foreign

 operations

 

-

 

364

Deferred tax on currency translation

-

(92)

Corporation tax on amount recycled to income statement

-

143

Tax recognised in statement of comprehensive income

(4)

249

Corporation tax on equity settled transactions

193

313

Deferred tax on equity settled transactions

166

(220)

Total tax recognised in equity

355

342

 

The 2011 Budget on 23 March 2011 announced that the UK corporation tax rate will reduce to 23% over a period of four years from 2011.  The first reduction in the UK corporation tax rate from 28% to 27% (effective from 1 April 2011) was substantively enacted on 20 July 2010, and further reductions to 26% (effective from 1 April 2011) and 25% (effective from 1 April 2012) were substantively enacted on 29 March 2011 and 5 July 2011 respectively.

 

This will reduce the Company's future current tax charge accordingly and further reduce the deferred tax liability at 30 June 2011 (which has been calculated based on the rate of 26% substantively enacted at 30 June 2011) by £14,000.

 

It has not yet been possible to quantify the full anticipated effect of the announced further 2% rate reduction, although this will further reduce the Company's future current tax charge and reduce the Company's deferred tax liability accordingly.

 

7.         Dividends


2011

£'000

 

2010

£'000

Final dividend paid in respect of prior year but not recognised as a

 liability in that year: 7.20p per share (2010: 6.10p)

 

4,764

 

4,000

 

Interim dividend paid: 3.70p per share (2010: 3.30p)

2,457

2,195

 

Total dividend 10.90p per share (2010: 9.40p) recognised as

 distributions to equity holders in the period

 

 

7,221

 

 

6,195

 

Proposed final dividend for the year ended

 30 June 2011: 8.40p per share (2010: 7.20p)

 

 

5,582

 

 

4,758

 

Total dividend paid and proposed for the year ended

 30 June 2011: 12.10p per share (2010: 10.50p)

 

 

8,039

 

 

6,953

 

In accordance with IAS 10 'Events After the Balance Sheet Date', the proposed final dividend for the year ended 30 June 2011 has not been accrued for in these financial statements.  It will be shown as a deduction from equity in the financial statements for the year ending 30 June 2012.

 

The proposed final dividend for the year ended 30 June 2010 is shown as a deduction from equity in the year ended 30 June 2011.



 

8.         Earnings per Share

Earnings per ordinary share have been calculated by dividing the profit attributable to equity holders of the parent after taxation for each financial period by the weighted average number of ordinary shares in issue during the period.


2011

Pence

2010

Pence

 

Basic earnings per share



- Underlying*

34.33

29.50

- Basic

21.33

19.97

 

Diluted earnings per share



- Underlying*

34.22

29.39

- Diluted

21.26

19.89

 

The calculations of basic and diluted earnings per share are based upon:




£'000

£'000

 

Earnings for underlying basic and underlying diluted earnings per share

 

22,748

 

19,437

Earnings for basic and diluted earnings per share

14,134

13,157


 

No.

 

No.

Weighted average number of ordinary shares for basic earnings per share

66,253,477

65,896,462

Impact of share options

221,013

241,438

 

Weighted average number of ordinary shares for diluted earnings per

 share

 

 

66,474,490

 

 

66,137,900

 

* Underlying measures exclude non-underlying items as defined on the Consolidated Income Statement

 

9.         Intangible Assets

 

 

 

Cost

 

Goodwill

£'000

 

Software

£'000

Development

Costs

£'000

Patent

Rights

£'000

Marketing

Authorisations

£'000

Acquired

Intangibles

£'000

 

Total

£'000

At 1 July 2009

21,105

2,097

4,914

2,783

853

68,879

100,631

Additions

-

447

955

76

-

-

1,478

Disposals

-

(1)

-

-

-

-

(1)

Foreign exchange adjustments

(609)

(21)

(13)

-

-

(2,120)

(2,763)

At 30 June 2010 and 1 July 2010

20,496

2,522

2,859

66,759

99,345

Additions

-

964

1,025

821

-

-

2,810

Acquisitions through business combinations

2,171

-

184

-

-

44,505

46,860

Disposals

-

-

-

-

-

-

-

Foreign exchange adjustments

1,582

62

37

-

-

3,738

5,419

At 30 June 2011

24,249

3,548

7,102

3,680

853

115,002

154,434

Amortisation






At 1 July 2009

-

497

623

111

-

9,835

11,066

Charge for the year

-

257

611

230

-

6,580

7,678

Impairment loss

-

-

-

230

-

-

230

At 30 June 2010 and 1 July 2010

-

754

571

16,415

18,974

Charge for the year

-

316

881

227

-

8,938

10,362

At 30 June 2011

-

1,070

2,115

798

-

25,353

29,336

Net book value








At 30 June 2011

24,249

2,478

4,987

2,882

853

89,649

125,098

At 30 June 2010 and 1 July 2010

20,496

1,768

4,622

2,288

853

50,344

80,371

At 30 June 2009

21,105

1,600

4,291

2,672

853

59,044

89,565



 

10.      Property, Plant and Equipment


Freehold

land and

buildings

£'000

Short

leasehold

buildings

£'000

 

Motor

vehicles

£'000

Plant

and

fixtures

£'000

 

 

Total

£'000

 

Cost






At 1 July 2009

2,326

2,932

201

9,524

14,983

Additions

-

395

-

848

1,243

Disposals

-

-

-

-

-

Foreign exchange adjustments

(70)

-

-

(31)

(101)

At 30 June 2010 and 1 July 2010

2,256

3,327

201

10,341

16,125

Additions

1

65

-

1,214

1,280

Acquisitions through business combinations

-

-

4

19

23

Disposals

-

(10)

-

(240)

(250)

Foreign exchange adjustments

190

-

-

93

283

At 30 June 2011

2,447

3,382

205

11,427

17,461

Depreciation






At 1 July 2009

196

1,019

201

5,527

6,943

Charge for the year

138

231

-

1,140

1,509

Disposals

-

-

-

-

-

At 30 June 2010 and 1 July 2010

334

1,250

201

6,667

8,452

Charge for the year

137

216

-

1,182

1,535

Disposals

-

(10)

-

(237)

(247)

At 30 June 2011

471

1,456

201

7,612

9,740

Net book value






At 30 June 2011

1,976

1,926

4

3,815

7,721

At 30 June 2010 and 1 July 2010

1,922

2,077

-

3,674

7,673

At 30 June 2009

2,130

1,913

-

3,997

8,040

Net book value of assets held under

 finance leases






At 30 June 2011

-

40

-

568

608

At 30 June 2010 and 1 July 2010

-

47

-

751

798

At 30 June 2009

-

55

-

970

1,025

 

11.      Deferred Taxes

Deferred tax assets and liabilities are attributable to the following:


Assets

Liabilities

Net


2011

£'000

2010

£'000

2011

£'000

2010

£'000

2011

£'000

2010

£'000

 

Intangible assets

-

-

(14,204)

(13,217)

(14,204)

(13,217)

Property, plant and equipment

-

-

(550)

(556)

(550)

(556)

Inventories

478

548

-

-

478

548

Receivables

41

49

-

-

41

49

Payables

161

173

(230)

(93)

(69)

80

Share-based payments

861

600

-

-

861

600


1,541

1,370

(14,984)

(13,866)

(13,443)

(12,496)

 

Deferred tax assets and liabilities are offset to the extent that there is a legally enforceable right to offset current tax assets against current tax liabilities.



 

12.      Inventories


2011

£'000

2010

£'000

 

Raw materials and consumables

5,170

4,129

Work in progress

371

336

Finished goods and goods for resale

35,219

30,354


40,760

34,819

 

13.      Trade and Other Receivables


2011

£'000

2010

£'000

 

Trade receivables

62,212

48,293

Other receivables

2,492

1,524

Prepayments and accrued income

1,589

1,345


66,293

51,162

 

14.      Cash and Cash Equivalents


2011

£'000

2010

£'000

 

Cash at bank and in hand

30,496

26,502

Short term deposits

-

5,000


30,496

31,502

 

15.      Trade and Other Payables


2011

£'000

2010

£'000

 

Trade payables

63,213

56,465

Other payables

4,770

2,991

Derivative financial instruments

397

573

Other taxation and social security

3,827

2,707

Accruals and deferred income

2,352

1,759


74,559

64,495

 

16.      Current Tax Liabilities


2011

£'000

2010

£'000

 

Corporation tax payable

5,391

4,105



 

17.      Borrowings


2011

£'000

2010

£'000

 

Current liabilities:



Bank loans

8,000

20,000

Finance lease obligations

502

441


8,502

20,441

Non-current liabilities:

Bank loans

55,746

17,500

Finance lease obligations

339

729

Arrangement fees netted off

-

(467)


56,085

17,762

Total borrowings

64,587

38,203

 

On 21 October 2010, the Group refinanced its existing bank facility, which gave rise to a loss on extinguishment of debt of £1,256,000.  The Group's revised borrowing facilities comprise a term loan of £40 million payable over four years, a £28 million revolving credit facility committed until 30 September 2014, an overdraft facility of £10 million (currently unutilised) renewable on 31 August 2012 and various finance lease obligations.

 

At the year end, the Group had the following unutilised borrowing facilities:


2011

£'000

2010

£'000

 

Bank overdraft facility

10,000

10,000

Revolving credit facility

254

-

 

18.      Share Capital


Ordinary shares of 1p each


2011

2010


£'000

No.

£'000

No.

 

Allotted, called up and fully

 paid at start of year

 

661

 

66,090,075

 

656

 

65,581,924

New shares issued

3

359,584

5

508,151

Allotted, called up and fully

 paid at end of year

 

664

 

66,449,659

 

661

 

66,090,075

 

The Companies Act 2006 abolishes the requirement for a company to have an authorised share capital.  At the 2009 Annual General Meeting Shareholders approved a resolution whereby all provisions relating to the Company's authorised share capital were removed from the Company's constitutional documents.

 

During the year 359,584 new ordinary shares of 1p (2010: 508,151 new ordinary shares of 1p) were issued following the exercise of options under the Executive Incentive Plan, and the Approved, Unapproved and SAYE Share Options Schemes.  The consideration received was £542,000 (2010: £589,000).  The holders of ordinary shares are entitled to receive dividends as declared or approved at General Meetings from time to time and are entitled to one vote per share at such meetings of the Company.



 

19.      Share-based Payments


2011

£'000

2010

£'000

 

Equity settled share-based transactions

830

817

Cash settled share-based transactions

118

93


948

910

 

The above charge to the Income Statement is included within administrative expenses.

 

20.      Analysis of Net Borrowings


2011

£'000

2010

£'000

 

Bank loans

(63,746)

(37,033)

Finance leases and hire purchase contracts

(841)

(1,170)

Cash and cash equivalents

30,496

31,502

Net borrowings

(34,091)

(6,701)

 

21.      Foreign Exchange Rates

The following exchange rates have been used in the translation of the results of foreign operations.

 


Closing rate at

30 June 2010

Average rate

Closing rate at

30 June 2011

 

Danish Krone

9.0983

8.614

8.256

Euro

1.2214

1.1556

1.1070

US Dollar

1.4961

1.5745

1.6073

 

22.      Acquisitions

Acquisition of DermaPet Inc.

On 22 October 2010, the Group acquired 100% of the share capital of DermaPet Inc., a Florida based business which develops and markets a range of dermatological preparations, including shampoos, conditioners and ear products, for the US and overseas companion animal markets. These veterinary products are marketed and distributed through the same channels as Dechra's current US product portfolio.

 

The acquisition of DermaPet Inc. increases Dechra's US presence and complements its EU range in this key strategic therapeutic category.



 


Book

value

£'000

Provisional

fair value

£'000

 

Recognised amounts of identifiable assets acquired and liabilities

 assumed



Identifiable assets



Trade and other receivables

1,084

1,084

Inventory

384

384

Identifiable intangible assets

-

38,909

Identifiable liabilities



Overdraft

(1)

(1)

Trade and other payables

(216)

(216)

Net identifiable assets

1,251

40,160

Goodwill


326

Total consideration


40,486

Satisfied by:



Cash


27,519

Deferred consideration


1,163

Contingent consideration arrangement


11,804

Total consideration transferred


40,486

Net cash outflow arising on acquisition



Cash consideration


27,519

Add: bank overdraft


1



27,520

 

The fair values shown above are provisional and may be amended if information not currently available comes to light.

 

The fair value of the financial assets includes trade receivables with a fair value of £1,076,000.

 

The fair value adjustment in relation to intangible assets recognises product rights in accordance with IFRS 3.

 

The goodwill of £326,000 arising from the acquisition consists of the assembled workforce and increased geographical presence in the US. The goodwill and identified intangibles are expected to be deductible for income tax purposes.

 

The deferred consideration arrangement requires payments of US$1,000,000 to be paid on the second and fourth anniversaries of the completion date. The contingent consideration arrangement requires if DermaPet Inc. achieves revenue in excess of US$15,000,000 in any rolling 12 month period commencing on the first anniversary of completion and ending on the sixth anniversary of completion, contingent consideration of US$15,000,000, which has been reassessed between the date of acquisition and the year end and remains unadjusted, will become payable. If revenue on the same criteria exceed US$20,000,000, a further US$5,000,000 will become due.

 

Acquisition related costs (included in non-underlying operating expenses) amounted to £585,000.

 

DermaPet Inc. contributed £4,993,000 revenue and £1,986,000 operating profit to the Group's profit for the period between the date of acquisition and the balance sheet date.

 

DermaPet Inc. has now been fully integrated into DVP US and its results are reported within the US Pharmaceuticals segment.



Acquisition of Genitrix Limited

On 1 December 2010, the Group acquired 100% of the share capital of Genitrix Limited. The acquisition of Genitrix Limited, a veterinary pharmaceuticals company based in Billingshurst, UK, is consistent with our strategy to grow our domestic and international pharmaceutical business.

 


Book

value

£'000

Provisional

fair value

£'000

 

Recognised amounts of identifiable assets acquired and liabilities

assumed



Identifiable assets



Intangible assets

184

184

Property, plant and equipment

27

23

Trade and other receivables

326

326

Inventory

217

217

Cash and cash equivalents

59

59

Identifiable intangible assets

-

5,596

Identifiable liabilities



Trade and other payables

(318)

(318)

Deferred tax liabilities

(36)

(1,546)

Net identifiable assets

4,541

Goodwill


1,845

Total consideration


6,386

Satisfied by:


Cash


5,586

Contingent consideration arrangement


800

Total consideration transferred


6,386

Net cash outflow arising on acquisition


Cash consideration


5,586

Less: cash and cash equivalent balances acquired


(59)



5,527

 

The fair values shown above are provisional and may be amended if information not currently available comes to light.

 

The fair value of the financial assets includes trade receivables with a fair value of £290,000.

 

The fair value adjustment in relation to intangible assets recognises product rights in accordance with IFRS 3.

 

The goodwill of £1,845,000 arising from the acquisition consists of the assembled workforce and associated technical expertise. None of the goodwill is expected to be deductible for income tax purposes.

 

The contingent consideration arrangement, which has been reassessed between the date of acquisition and the year end and remains unadjusted, requires payment of £800,000 to be paid on the achievement of specific milestones.

 

Genitrix Limited has now been fully integrated into DVP EU and its results are reported within the European pharmaceutical segment.

 

Acquisition related costs (included in non-underlying operating expenses) amounted to £108,000.



Genitrix Limited contributed £1,565,000 revenue and £736,000 operating profit to the Group's profit for the period between the date of acquisition and the balance sheet date.

 

If the acquisitions of DermaPet Inc. and Genitrix Limited had been completed on the first day of the financial year, Group revenues for the period would have been £393,754,000 and underlying pre-tax profit would have been £31,263,000.

 

23.      Contingent Liability

The Danish tax authorities are continuing their investigation into the tax return of Dechra Veterinary Products Holding A/S (formerly Vetxx® Holding A/S) for the period ended 31 December 2005, a period prior to the acquisition of the company.  They are seeking to reduce the tax losses arising in this year by DKK17.5 million.  They have also indicated that they will be investigating the tax returns for 2006, 2007 and 2008.  The Directors believe that there are strong arguments to resist this claim.  However, should the dispute be lost, the deferred tax asset recognised on acquisition would be reduced by approximately £1.3 million.

 

24.      Other Information

The financial information set out above does not constitute the Company's statutory accounts for the years ended 30 June 2011 or 2010 but is derived from the 2011 accounts. Statutory accounts for 2010 have been delivered to the Registrar of Companies and those for 2011 will be delivered in due course. The Auditor has reported on those accounts; the report was (i) unqualified, (ii) did not include references to any matters to which the auditor drew attention by way of emphasis without qualifying the reports and (iii) did not contain statements under section 498(2) or (3) of the Companies Act  2006.

 

25.     Preliminary Statement

This Preliminary statement is not being posted to Shareholders.  The Report & Accounts for the year ended 30 June 2011 will be posted to Shareholders shortly.  Further copies will be available from the Company's Registered Office: Dechra House, Jamage Industrial Estate, Talke Pits, Stoke on Trent, ST7 1XW.  Email: corporate.enquiries@dechra.com.  Copies are also available on the Company website www.dechra.com.

 

26.     Directors' Responsibility Statement Required under the Disclosure and Transparency Rules

The responsibility statement below has been prepared in connection with the Company's full Annual Report for the year ended 30 June 2011.  Certain parts of that Report are not included with this announcement.

 

We confirm to the best of our knowledge:

a)       the financial statements, prepared in accordance with International Financial Reporting Standards as adopted by the European Union, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; and

 

b)       the management report, which comprises the Directors' Report, includes a fair review of the development and performance of the Business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.

 

Approved by the Board and signed on its behalf by:

 

Ian Page

Simon Evans

Chief Executive

Group Finance Director

 

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.  The Malaseb Trademark is used under licence from Dermcare-Vet Pty. Ltd.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EASNSESSFEFF
UK 100

Latest directors dealings